WitowskiJ., JörresA., KorybalskaK., KsiazekK., Wisniewska– ElnurJ., BenderT.O.Glucose degradation products in peritoneal dialysis fluids: do they harm?Kidney Int Suppl2003; (84): S148–51.
3.
HoffC.M.In vitro biocompatibility performance of Physioneal.Kidney Int Suppl2003; (88): S57–74.
4.
MactierR.A., SprosenT.S., GokalR., WilliamsP.F., LindberghM., NaikR.B.Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.Kidney Int1998; 53: 1061–7.
5.
KredietR.T., ZweersM.M., van der WalA.C., StruijkD.G.Neoangiogenesis in the peritoneal membrane.Perit Dial Int2000; 20(Suppl 2): S19–25.
6.
SchambyeH.T.Effect of different buffers on the biocompatibility of CAPD solutions.Perit Dial Int1996; 16(Suppl 1): S130–6.
7.
WitowskiJ., JörresA.Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences.Perit Dial Int2005; 25(Suppl 3): S31–4.
8.
NauB., SchmittC.P., AlmeidaM., ArbeiterK., ArdissinoG., BonzelK.E.BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in bio-compatible peritoneal dialysis solutions in children [ISRCTN81137991].BMC Nephrol2004; 5: 14.
9.
OhE.J., RyuH.M., ChoiS.Y., YookJ.M., KimC.D., ParkS.H.Impact of low glucose degradation product bicarbonate/ lactate–buffered dialysis solution on the epithelial– mesenchymal transition of peritoneum.Am J Nephrol2010; 31: 58–67.
McIntyreC.W.Update on peritoneal dialysis solutions.Kidney Int2007; 71: 486–90.
12.
MortierS., FaictD., SchalkwijkC.G., LameireN.H., De VrieseA.S.Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane.Kidney Int2004; 66: 1257–65.
13.
MortierS., FaictD., LameireN.H., De VrieseA.S.Benefits of switching from a conventional to a low-GDP bicarbonate/ lactate–buffered dialysis solution in a rat model.Kidney Int2005; 67: 1559–65.
14.
MackenzieR., HolmesC.J., JonesS., WilliamsJ.D., TopleyN.Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients.Kidney Int Suppl2003; (88): S84–93.
15.
LeeH.Y., ParkH.C., SeoB.J., DoJ.Y., YunS.R., SongH.Y.Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).Perit Dial Int2005; 25: 248–55.
16.
LeeH.Y., ChoiH.Y., ParkH.C., SeoB.J., DoJ.Y., YunS.R.Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.Nephrol Dial Transplant2006; 21: 2893–9.
17.
HanS.H., AhnS.V., YunJ.Y., TranæusA., HanD.S.Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions.Am J Kidney Dis2009; 54: 711–20.
18.
JohnsonD.W., WilliamsJ.D.Impact of peritoneal dialysis solutions on outcomes. In: MolonyD.A., CraigJ.C., eds. Evidence-Based Nephrology.Oxford, UK: Blackwell; 2009.
19.
TranæusA.A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution–clinical benefits. The Bicarbonate/Lactate Study Group.Perit Dial Int2000; 20: 516–23.
20.
le PooleC.Y., van IttersumF.J., WeijmerM.C., ValentijnR.M., ter WeeP.M.Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.Adv Perit Dial2004; 20: 170–6.
21.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.on behalf of the Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
22.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
23.
ChoiH.Y., KimD.K., LeeT.H., MoonS.J., HanS.H., LeeJ.E.The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.Perit Dial Int2008; 28: 174–82.
24.
FanS.L., PileT., PunzalanS., RafteryM.J., YaqoobM.M.Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.Kidney Int2008; 73: 200–6.
25.
KimS., OhJ., KimS., ChungW., AhnC., KimS.G.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.Nephrol Dial Transplant2009; 24: 2899–908.
26.
WeissL., StegmayrB., MalmstenG., TejdeM., HadimeriH., SiegertC.E.Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.Perit Dial Int2009; 29: 647–55.
27.
Haag-WeberM., KrämerR., HaakeR., IslamM.S., PrischlF., HaugU.on behalf of the DIUREST Study Group. Low-GDP fluid (Gambrosol Trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.Nephrol Dial Transplant2010; 25: 2288–96.
28.
SrivastavaS., HildebrandS., FanS.L.Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival.Kidney Int2011; 80: 986–91.
29.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.on behalf of the BalANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; :[Epub ahead of print].
30.
LaiK.N., LamM.F., LeungJ.C.K., ChanL.Y., LamC.W.K., ChanI.H.S.A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.Perit Dial Int2012; 31: 280–291.
31.
JohnsonD.W., ClarkeM., WilsonV., WoodsF., BrownF.G.Rationale and design of the BalANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.BMC Nephrol2010; 11: 25.
32.
HimmeleR., JensenL., FennD., HoC.H., SawinD.A., Diaz-BuxoJ.A.A new neutral-pH low-GDP peritoneal dialysis fluid.Perit Dial Int2012; :[Epub ahead of print].
